Melanotan II is a synthetic melanocyte-stimulating hormone analog that triggers melanin production for sun-independent tanning. Developed in the 1980s as a potential melanoma prevention strategy, it produces deep skin pigmentation with minimal UV exposure, but carries significant side effects including persistent moles, nausea, and unpredictable libido effects. The honest case for melanotan II is narrow: pale users who burn rather than tan, who have already accepted the risks, and who use the lowest effective dose. This guide covers melanotan II honestly, the trial data, dosing, real side effects, and the health considerations most articles ignore.
Melanotan II is one of the more controversial peptides. It works for what it claims (tanning) but the side effect profile is real, and the long-term safety questions are not resolved. We list it in our catalog because customers ask for it, but we always discuss the risks before shipping.
What Is Melanotan II?
Melanotan II is a synthetic 7-amino-acid cyclic peptide analog of alpha-melanocyte stimulating hormone (alpha-MSH). It binds melanocortin receptors (MC1R primarily for tanning, plus MC3R, MC4R, MC5R for various other effects).
The original Arizona university research aimed at melanoma prevention by stimulating protective melanin production. The effect on tanning was the desired target, but the broad melanocortin receptor activation produces multiple unintended effects.
Melanotan II Effects
Skin tanning (the intended use)
MC1R activation in melanocytes triggers eumelanin production. Result: darker skin pigmentation that develops over 2 to 4 weeks of consistent dosing. The tan persists 1 to 3 months after stopping, depending on individual melanin retention.
For pale-skinned users (skin types I and II in the Fitzpatrick scale) who burn rather than tan, melanotan II produces the kind of tan natural sun exposure cannot achieve.
Libido and arousal effects (often unintended)
MC4R activation triggers central arousal pathways. Many users experience increased libido and spontaneous erections (in men) during melanotan II cycles. This is what led to PT-141 development as a libido-isolated derivative.
Effect is dose-dependent and varies widely. Some users find the libido effect welcome; others find it disruptive.
Appetite suppression
Mild appetite reduction during cycles, mediated by MC4R activation in the hypothalamus. Users sometimes notice weight loss alongside the tanning.
Skin darkening of moles and freckles
This is the major aesthetic concern. Melanotan II darkens existing moles and can cause new moles to appear. The changes are often permanent and may require dermatological monitoring.
Melanotan II Dosing Protocol
Two-phase protocol:
Loading phase (2 to 4 weeks)
- Dose: 0.25 to 0.5 mg subcutaneous, daily
- UV exposure: 5 to 10 minutes of sun or tanning bed every 2 to 3 days while dosing
- Goal: build to desired tan color
Maintenance phase
- Dose: 0.25 to 0.5 mg, 1 to 2 times per week
- UV exposure: 5 to 10 minutes weekly to maintain
Critical: melanotan II does not eliminate the need for some UV exposure. The mechanism is “melanin production with less UV”, not “melanin production without UV”. Skipping all sun exposure on melanotan II produces patchy or no tanning.
Reconstitution
Standard 10 mg vial:
- Add 1 mL bacteriostatic water → 10 mg/mL
- 0.25 mg dose = 0.025 mL (2 to 3 units)
- 0.5 mg dose = 0.05 mL (5 units)
Refrigerate after reconstitution; stable 30 days.
Melanotan II Side Effects
The side effect profile is the main reason most people start with low doses or stop after a single cycle:
- Nausea (60 to 80% of users at 1 mg+ dose): most common side effect. Worst on the first few injections; usually subsides as the body adapts.
- Facial flushing: red flushing in face and chest within 30 minutes of injection. Resolves within 2 hours.
- Increased libido and spontaneous erections: for men, sometimes inconvenient.
- Mole darkening and new moles: significant aesthetic concern. Existing moles darken; new moles can appear, often requiring dermatologist evaluation.
- Persistent skin darkening: the tan does not fully fade between cycles. Cumulative skin darkening occurs with multiple cycles.
- Loss of appetite: usually mild but can be significant in some users.
- Increased blood pressure: 5 to 8 mmHg systolic during cycles.
- Yawning and stretching: known melanocortin side effects, sometimes pronounced.
Long-Term Safety Concerns
What is not well-resolved:
- Mole biology: the new moles that appear during melanotan II use are typically benign nevi, but increased mole load is a known melanoma risk factor in epidemiology. Whether melanotan II-induced moles carry the same lifetime risk as natural moles is unstudied.
- Melanoma risk: melanotan II was originally developed for melanoma prevention via increased melanin protection. Whether long-term use actually achieves this protective effect or paradoxically increases risk through mole induction is unclear.
- Cardiovascular effects: chronic use elevates BP modestly. Long-term cardiovascular risk in users running multiple cycles per year is unknown.
- Reversibility: most melanotan II effects reverse on stopping, but mole changes may be permanent.
The honest framing: melanotan II works for tanning, but the long-term safety profile is poorly characterized. Use cautiously, monitor mole changes, and limit cumulative exposure.
Who Should Consider Melanotan II
- Pale-skinned users (Fitzpatrick I or II) who burn rather than tan
- Users planning a beach trip who want background tan to reduce burn risk
- Users who have weighed the mole and long-term safety concerns and accepted them
- Users with regular dermatological monitoring
Who Should Avoid Melanotan II
- Users with personal or family history of melanoma or skin cancer
- Users with many existing moles (the new mole risk is amplified)
- Users with hypertension
- Pregnant or breastfeeding women
- Users prone to nausea or sensitive to GI side effects
- Users seeking the libido effect (use PT-141 instead, which isolates that effect)
Melanotan II vs PT-141 vs Self-Tanner
| Method | Effect | Onset | Side effects | Health risk |
|---|---|---|---|---|
| Melanotan II | Real tan via melanin | 2 to 4 weeks | Nausea, mole changes, persistent | Significant |
| PT-141 | Libido (no tanning) | 30 to 60 min | Nausea, BP, transient | Moderate |
| Sun exposure | Real tan, gradual | Weeks of consistent exposure | UV damage, skin cancer risk | Significant |
| Tanning bed | Real tan, faster | Days to weeks | UV damage | Higher than natural sun |
| Self-tanner (DHA) | Cosmetic stain | Hours | Skin staining only | Negligible |
For users seeking only tanning without health risks, modern self-tanners produce realistic results without UV or peptide use. Melanotan II makes sense only for users who specifically want melanin-based protection (not just cosmetic color) and accept the trade-offs.
Common Melanotan II Mistakes
- Starting at full dose: 1 mg first injection produces severe nausea. Start at 0.1 to 0.25 mg and titrate up.
- Skipping all UV exposure: melanotan II without any sun produces uneven results. Modest UV is needed.
- Not monitoring moles: get a baseline dermatological mole map before starting and re-evaluate annually if cycling repeatedly.
- Stacking with PT-141: redundant mechanism, amplified side effects. Use one or the other.
- Continuous use beyond 12 weeks: receptor desensitization plus cumulative side effect risk. Cycle properly.
Frequently Asked Questions
How long does the melanotan II tan last?
The tan persists 1 to 3 months after stopping the peptide and reducing UV exposure. Longer than natural tans because the melanin was deposited more deeply in the skin layers.
Is melanotan II legal?
Status varies by country. Banned in some EU countries (UK, Australia). Research-use legal in others. See our peptide legal status guide.
Will the new moles go away?
Usually no. New moles induced by melanotan II are typically permanent. This is the most concerning long-term consequence and the reason regular dermatological monitoring is recommended.
Does melanotan II prevent skin cancer?
Theoretically, increased melanin offers some UV protection. But the increased mole burden may offset this benefit or even increase risk. Net effect on skin cancer risk is unresolved.
Can I use melanotan II year-round?
Not recommended. Cycle 8 to 12 weeks on, 12 weeks off. Continuous year-round use accumulates side effects and unknown long-term risks.
Where can I get melanotan II?
For research-grade melanotan II in Indonesia and Southeast Asia, see our pricelist. We discuss the side effect profile and risks with every first-time customer before shipping.
This article is for informational and research-use purposes only. Melanotan II is not approved by the FDA or EMA for human use. Always consult a qualified medical professional and dermatologist before considering use.